BeneTalk secures £350k in funding alongside a £380k Innovate UK grant to advance speech therapy technology.
The speech therapy technology company drew backing from Henley Business Angels and Innovate UK.
BeneTalk builds wearable speech therapy technology designed to help people who stutter practise and maintain fluency techniques. The company combines artificial intelligence with digital tracking to support out of the clinic treatment.
BeneTalk has secured a total funding round of £350k, featuring equity investment from a member of Henley Business Angels. The company also received a £380k grant from Innovate UK to support its technology development.
The fresh capital will be directed towards accelerating the firm's technical research and development programme. These financial injections build on previous backing from various accelerators and public bodies as the business advances its pre launch activities.
From the founder
"This latest investment shows the belief in the BeneTalk product and team, and helps us move closer to transforming the speech therapy experience for millions of people with our AI-driven speech-tracking technology."
Jordi Fernandez
CEO at BeneTalk
Use of funds
- 01Fund research and development
Investors
Categories
About the company
BeneTalk
BeneTalk develops wearable technology and artificial intelligence tools for speech therapy.